导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.43% | 3551/4773 |
| 近一周 | -1.66% | 2476/5465 |
| 近一月 | -7.80% | 4686/5421 |
| 近一季 | 5.68% | 303/5231 |
| 近半年 | -6.81% | 3258/4920 |
| 近一年 | -16.67% | 3839/4394 |
| 近两年 | 13.16% | 2768/2954 |
| 近三年 | -10.63% | 2038/2253 |
| 成立以来 | -23.44% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.94% 2024/4961 |
-8.60% 3902/5312 |
- - |
- - |
| 2025 | 4.88% 3027/4813 |
1.66% 1576/3635 |
2.75% 1386/4076 |
9.58% 3344/4524 |
-8.37% 3908/4813 |
| 2024 | -10.54% 2345/3463 |
-9.93% 2307/2808 |
-5.85% 1809/3014 |
15.96% 1578/3129 |
-9.03% 2896/3463 |
| 2023 | -9.87% 1241/2656 |
1.33% 1596/2280 |
-7.43% 1853/2385 |
-3.51% 945/2515 |
-0.42% 212/2655 |
| 2022 | -17.57% 606/2207 |
-12.95% 673/1919 |
-0.54% 1634/2016 |
-14.21% 1048/2113 |
10.99% 159/2208 |
| 2021 | -1.45% 801/1822 |
-0.73% 390/1255 |
10.50% 458/1330 |
-12.37% 1305/1466 |
2.52% 573/1822 |
| 2020 | 42.36% 271/1250 |
9.33% 26/1028 |
29.10% 85/1067 |
3.27% 988/1164 |
-2.33% 1120/1184 |
| 2019 | 33.14% 437/1092 |
27.15% 357/739 |
-7.63% 565/788 |
8.15% 68/850 |
4.81% 779/918 |
| 2018 | -24.03% 313/834 |
- - |
-2.68% 70/631 |
-14.04% 646/660 |
-14.34% 583/682 |
| 2017 | 3.20% 429/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.05% 348/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 天弘中证医药100C VS. 长安沪深300非周期A(740101) |